Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6199 | Cardionogen 1 |
| Wnt signaling modulator. Potently inhibits Wnt/β-catenin-dependent transcription in murine ES cells (EC50 = 23 nM) and zebrafish embryos. Enlarges heart size via cardiomyocyte hyperplasia; induces ES cell cardiac differentiation. | |
| BCC6200 | A 844606 |
| Selective α7 nicotinic acetylcholine receptor (nAChR) partial agonist (EC50 values are 1.4 and 2.2 μM at human and rat receptors respectively). Displays no measurable effect on α4β2 nAChRs. Stimulates α7 nAChR-induced ERK1/2 phosphorylation in PC12 cells. | |
| BCC6203 | A 484954 |
| Inhibitor of eukaryotic elongation factor-2 (eEF-2) kinase (IC50 = 0.28 μM in enzymatic assay). Reduces eEF-2 phosphorylation with little effect on cancer cell growth. | |
| BCC6204 | 1-Deazaadenosine |
| Inhibitor of adenosine deaminase (Ki = 0.66 μM). Demonstrates antitumor activity in a range of leukemia cell lines. | |
| BCC6205 | DQP 1105 |
| Noncompetitive NMDA receptor antagonist; displays over 50-fold selectivity for GluN2D- and GluN2C-containing receptors over GluN2B-, GluK2-, GluA1- and GluN2A-containing receptors (IC50 values are 2.7, 8.5, 121, 153, 198 and 206 μM, respectively). Reduces frequency of channel opening. | |
| BCC6206 | Y 11 |
| Potent inhibitor of focal adhesion kinase (FAK); prevents FAK autophosphorylation at the Y397 site (IC50 ~ 50 nM in an in vitro kinase assay). Displays selectivity for FAK over a panel of other kinases (concentration used in assay = 1 μM). Decreases cell viability in a number of cancer cell lines; blocks colony formation in SW620 and BT474 cell lines. | |
| BCC6208 | S 32212 hydrochloride |
| Inverse agonist of 5-HT2C receptors (pKi = 8.18 at human 5-HT2C INI receptors). Also an antagonist of human α2-adrenoceptors. Displays negligible affinity for α1A-adrenoceptors, histamine H1 receptors and muscarinic M1 receptors. | |
| BCC6209 | STF 083010 |
| Inhibitor of IRE1α endonuclease activity; blocks endogenous XBP1 mRNA splicing. Displays cytostatic and cytotoxic effects in CD138+ multiple myeloma (MM) cells in vitro; inhibits bortezomib-induced XBP1 activity in myeloma xenografts in vivo. Does not alter IRE1α kinase activity. | |
